Hannah Wuisan
Primary Care · Birmingham, ALNPI 1750915625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $809 and has fallen 56.1% since, to $355 in 2025.
Across 19 payments — averaging $113.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$484
- AbbVie$412
- Novo Nordisk$230
- Esperion Therapeutics, Inc.$125
- Axsome Therapeutics, Inc.$125
- Regeneron Healthcare Solutions, Inc.$122
- plus $659 from 6 others
What the payments were for
- Food & beverage$2,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $484 |
| AbbVie | 4 | $412 |
| Novo Nordisk | 2 | $230 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Bayer | 1 | $118 |
| Ultragenyx Pharmaceutical Inc. | 1 | $116 |
| Merck | 1 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $113 |
| Corcept Therapeutics | 1 | $99 |
| Alkermes, Inc. | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,155 in reported general payments places this provider in the 70th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $11,499 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $878 |
| Atorvastatin Calcium | 57 | $812 |
| Amlodipine Besylate | 73 | $701 |
| Rosuvastatin Calcium | 19 | $572 |
| Pantoprazole Sodium | 24 | $383 |
| Olmesartan Medoxomil | 11 | $353 |
| Losartan Potassium | 26 | $337 |
| Levothyroxine Sodium | 25 | $329 |
| Omeprazole | 19 | $274 |
| Lisinopril | 19 | $181 |
| Fluticasone Propionate | 17 | $171 |
| Carvedilol | 12 | $146 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $130 |
| Escitalopram Oxalate | 12 | $106 |
Paid to pharmacies, not to this prescriber.
Other primary care in Birmingham
- Josh WarrenBirmingham$9K
- Jill AroraBirmingham$6K
- Bevin EllenbergBirmingham$5K
- Samantha WilliamsBirmingham$4K
- Barbara BoreenBirmingham$4K
- Joanna ReavesBirmingham$3K
- Anna MesserBirmingham$2K
- Tiffany LasernaBirmingham$2K
- Holly StraussBirmingham$2K
- Brooke LittleBirmingham$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.